$303,999,997

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactive

ACTION DATE2026-03-04·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50124F61002_7505_75A50123D00003_7505

Award description

OTHER TRANSACTION: PRODUCTION OF DRUG SUBSTANCES AND DRUG PRODUCTS AT COMMERCIAL SCALE UNDER BIOMAP-CONSORTIUM

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Scale-up production of drug substances and products at commercial manufacturing capacity under the BIOMAP consortium.

Sub-sectors

pharmaceutical-manufacturingdrug-productionbiosecurity

Why this matters

Strengthens domestic pharmaceutical manufacturing resilience and reduces reliance on foreign drug production capacity during health emergencies.

Supply-chain signal

Signals investment in expanding U.S. contract manufacturing organizations (CMOs) and domestic active pharmaceutical ingredient (API) production capabilities.

U.S.–China competition angle

Reduces U.S. dependence on Chinese and Indian pharmaceutical manufacturing, addressing critical supply chain vulnerabilities identified post-COVID.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-14. Cost: $0.001357.

Period of performance

Start

2024-01-12

End

2030-03-01

Status

activein 1386 days

Sources

Award record ingested from usaspending. Source identifier CONT_AWD_75A50124F61002_7505_75A50123D00003_7505.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.